MX2022001022A - Anticuerpo biespecifico anti-her2/anti-4-1bb y uso del mismo. - Google Patents

Anticuerpo biespecifico anti-her2/anti-4-1bb y uso del mismo.

Info

Publication number
MX2022001022A
MX2022001022A MX2022001022A MX2022001022A MX2022001022A MX 2022001022 A MX2022001022 A MX 2022001022A MX 2022001022 A MX2022001022 A MX 2022001022A MX 2022001022 A MX2022001022 A MX 2022001022A MX 2022001022 A MX2022001022 A MX 2022001022A
Authority
MX
Mexico
Prior art keywords
same
her2
antibody
biaspecific
cancer
Prior art date
Application number
MX2022001022A
Other languages
English (en)
Spanish (es)
Inventor
Na Rae Lee
Taewang Kim
Moo Young Song
Seawon Ahn
Donghoon Yeom
Young Bong Park
Eunyoung Park
Yangsoon Lee
Hyejin Chung
Eunjung Kim
Yong-Gyu Son
Yeryoung Yong
Ui-Jung Jung
Kyeongsu Park
Wonjun Son
Eun-Jung Lee
Eun Jung Lee
Chanmoo Lee
Junghyeon Hong
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of MX2022001022A publication Critical patent/MX2022001022A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2022001022A 2019-07-26 2020-07-27 Anticuerpo biespecifico anti-her2/anti-4-1bb y uso del mismo. MX2022001022A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962878951P 2019-07-26 2019-07-26
US202063024608P 2020-05-14 2020-05-14
PCT/KR2020/009871 WO2021020846A1 (en) 2019-07-26 2020-07-27 Anti-her2/anti-4-1bb bispecific antibody and use thereof

Publications (1)

Publication Number Publication Date
MX2022001022A true MX2022001022A (es) 2022-04-18

Family

ID=74190718

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001022A MX2022001022A (es) 2019-07-26 2020-07-27 Anticuerpo biespecifico anti-her2/anti-4-1bb y uso del mismo.

Country Status (11)

Country Link
US (2) US12240913B2 (enExample)
EP (1) EP4004054A4 (enExample)
JP (2) JP7725446B2 (enExample)
KR (2) KR102820082B1 (enExample)
CN (2) CN118638240A (enExample)
AU (1) AU2020320233A1 (enExample)
BR (1) BR112022001336A8 (enExample)
CA (1) CA3147423A1 (enExample)
MX (1) MX2022001022A (enExample)
WO (1) WO2021020846A1 (enExample)
ZA (1) ZA202200906B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11261259B2 (en) 2019-08-12 2022-03-01 I-Mab Biopharma Us Limited Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof
KR20220145859A (ko) * 2020-02-28 2022-10-31 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물, 다중 특이적 항체 및 그 용도
WO2022029496A1 (en) * 2020-08-07 2022-02-10 Eutilex Co., Ltd. Anti-her2 / anti-4-1bb bispecific antibodies and uses thereof
JP7875865B2 (ja) * 2021-01-25 2026-06-18 ユーハン・コーポレイション 抗４－１ｂｂ／抗ｈｅｒ２二重特異性抗体の精製方法
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
CA3237165A1 (en) * 2021-11-19 2023-05-25 Jeng-Horng Her Bispecific antibodies targeting cd137 and uses thereof for anti-cancer immunotherapy
EP4504790A4 (en) * 2022-04-07 2026-04-08 Yuhan Corp Pharmaceutical composition for treating or preventing cancer with low HER2 expression
KR20250148463A (ko) * 2024-04-03 2025-10-14 주식회사유한양행 담도암의 치료를 위한 항-her2/항-4-1bb 이중 특이 항체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100694508B1 (ko) * 2005-05-24 2007-03-13 울산대학교 산학협력단 Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
US20140178368A1 (en) * 2011-04-19 2014-06-26 Leslie Lynne SHARP Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
WO2016149665A1 (en) * 2015-03-18 2016-09-22 Baylor College Of Medicine Her2/erbb2 chimeric antigen receptor
RU2727165C2 (ru) * 2015-05-04 2020-07-21 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
US10017577B2 (en) * 2015-06-15 2018-07-10 Genentech, Inc. Antibodies and immunoconjugates
SG11201808196UA (en) * 2016-03-31 2018-10-30 Neon Therapeutics Inc Neoantigens and methods of their use
BR112018071612A2 (pt) * 2016-04-22 2019-02-19 Alligator Bioscience Ab polipeptídeos biespecíficos inovadores contra cd137
CA3042049A1 (en) * 2016-11-03 2018-05-11 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and a btk inhibitor
BR112019017628A2 (pt) * 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
US11725060B2 (en) 2017-07-20 2023-08-15 Aptevo Reserch and Development LLC Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods
SG11202105152YA (en) * 2018-11-30 2021-06-29 Abl Bio Inc Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof

Also Published As

Publication number Publication date
AU2020320233A8 (en) 2022-02-24
US12240913B2 (en) 2025-03-04
EP4004054A4 (en) 2023-10-25
ZA202200906B (en) 2023-11-29
CA3147423A1 (en) 2021-02-04
JP7725446B2 (ja) 2025-08-19
BR112022001336A2 (pt) 2022-03-22
WO2021020846A1 (en) 2021-02-04
CN114206941A (zh) 2022-03-18
CN118638240A (zh) 2024-09-13
KR102820082B1 (ko) 2025-06-13
KR20220038768A (ko) 2022-03-29
US20210024650A1 (en) 2021-01-28
CN114206941B (zh) 2024-07-02
JP2025179060A (ja) 2025-12-09
KR20250090381A (ko) 2025-06-19
JP2022542574A (ja) 2022-10-05
AU2020320233A1 (en) 2022-02-17
US20250163180A1 (en) 2025-05-22
EP4004054A1 (en) 2022-06-01
BR112022001336A8 (pt) 2023-02-07

Similar Documents

Publication Publication Date Title
MX2022001027A (es) Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo.
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
BR112022001336A2 (pt) Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo
DK4067387T3 (da) Bispecifikt anti-pd-1-anti-vegfa-antistof, farmaceutisk sammensætning og anvendelse deraf
CL2021000084A1 (es) Inhibidores de pd-1/pd-l1
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
UY38353A (es) Inhibición de integrina alfavbeta6
PE20210167A1 (es) Proteinas de union multiespecificas y mejoras con estas
MX2019013858A (es) Inhibidores de kras g12c y metodos para su uso.
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
CL2022000087A1 (es) Anticuerpo anti-tau y uso del mismo
PH12022550646A1 (en) Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
MX2024012294A (es) RECEPTORES DE TGF-ß Y MÉTODOS DE USO
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
ZA202211405B (en) Anti-cd73-anti-pd-1 bispecific antibody and use thereof
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
ZA202309150B (en) Antibody against nkp46 and application of antibody
PH12020552159A1 (en) Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
MX2018013484A (es) Nuevos anticuerpos anti-tnfrsf21 y modos de uso.
CU20220019A7 (es) Proteínas de fusión nkg2d
MX2024011128A (es) Molecula de union a antigeno que se une especificamente a gprc5d y cd3 y su uso medico.
MX2023015070A (es) Anticuerpo anti-cd40, fragmento de union a antigeno y uso medico del mismo.
MX2020004074A (es) Producto de combinacion para el tratamiento de cancer.
CL2022000752A1 (es) Molécula de unión específica para lif y uso de la misma